Neos Therapeutics (NEOS) Given a $20.00 Price Target at Cantor Fitzgerald
NEOS has been the subject of several other reports. Zacks Investment Research downgraded Neos Therapeutics from a strong-buy rating to a hold rating in a report on Tuesday, September 12th. Wells Fargo & Co set a $14.00 price objective on Neos Therapeutics and gave the stock a buy rating in a research report on Wednesday, October 18th. BidaskClub upgraded Neos Therapeutics from a sell rating to a hold rating in a research report on Wednesday, December 27th. Finally, Cowen reiterated a buy rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $14.00.
Shares of Neos Therapeutics (NASDAQ:NEOS) traded down $0.03 during midday trading on Monday, hitting $10.37. The company had a trading volume of 203,668 shares, compared to its average volume of 310,078. The company has a current ratio of 2.42, a quick ratio of 2.14 and a debt-to-equity ratio of 4.01. Neos Therapeutics has a 52-week low of $4.85 and a 52-week high of $13.15. The firm has a market capitalization of $301.57 and a P/E ratio of -3.03.
Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.22. Neos Therapeutics had a negative return on equity of 325.92% and a negative net margin of 242.84%. The firm had revenue of $6.70 million during the quarter. research analysts expect that Neos Therapeutics will post -2.87 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in NEOS. Schwab Charles Investment Management Inc. raised its position in Neos Therapeutics by 103.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock worth $320,000 after acquiring an additional 22,200 shares in the last quarter. Rhumbline Advisers raised its position in Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock worth $149,000 after acquiring an additional 2,441 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in Neos Therapeutics in the second quarter worth $102,000. Wells Fargo & Company MN raised its position in Neos Therapeutics by 13.0% in the second quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock worth $396,000 after acquiring an additional 6,223 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new position in Neos Therapeutics in the second quarter worth $161,000. Hedge funds and other institutional investors own 45.75% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.